Pharmacokinetic interaction study evaluating the effect of BMS-275291 on the pharmacokinetics of paclitaxel and carboplatin in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Malik, SM
Hwang, JJ
Belani, CP
Galbraith, S
Bai, S
Rizvi, NA
机构：
[1] Lombardi Canc Ctr, Washington, DC USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7309
引用
收藏
页码：693S / 693S
页数：1
相关论文
共 50 条
  • [1] Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer
    Douillard, JY
    Peschel, C
    Shepherd, F
    Paz-Ares, L
    Arnold, A
    Davis, M
    Tonato, M
    Smylie, M
    Tu, DS
    Voi, M
    Humphrey, J
    Ottaway, J
    Young, K
    Van Vreckem, A
    Seymour, L
    LUNG CANCER, 2004, 46 (03) : 361 - 368
  • [2] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
  • [3] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Rodon, Jordi
    Jacobs, Charlotte D.
    Chu, Quincy
    Rowinsky, Eric K.
    Lopez-Anaya, Arturo
    Takimoto, Chris H.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 825 - 834
  • [4] Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18.
    Leighl, NB
    Shepherd, F
    Paz-Ares, L
    Douillard, JY
    Peschel, C
    Arnold, A
    Tu, D
    Galbraith, S
    Hann, K
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 626S - 626S
  • [5] Paclitaxel Carboplatin in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Kanat, Ozkan
    Cubukcu, Erdem
    Cubukcu, Sinem
    Aksoy, Savas
    Canhoroz, Mustafa
    Karadag, Oya
    Alkis, Nihan
    Manavolglu, Osman
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2012, 3 (03) : 293 - 295
  • [6] Paclitaxel and Carboplatin in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Sadic, Murat
    Alavi, Abass
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2016, 7
  • [7] Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)
    Fabi, A
    De Marco, S
    Barduagni, M
    Gamucci, T
    Cortesi, E
    De Marinis, F
    Ferraresi, V
    Saltarelli, R
    Gabriele, A
    Accettura, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [8] Concurrent chemoradiotherapy with paclitaxel and carboplatin for locoregionally advanced non-small cell lung cancer (NSCLC)
    Kaplanova, J.
    Tomiskova, M.
    Babickova, L.
    Kadlec, B.
    Slampa, P.
    Skrickova, J.
    LUNG CANCER, 2006, 52 : S34 - S34
  • [9] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    LUNG CANCER, 2005, 49 : S272 - S272
  • [10] Assessment of pharmacokinetic (PK) interactions between Carboplatin (C), Paclitaxel (P) and ABT-869 in patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Gupta, Neeraj
    Palaparthy, Rameshraja
    Awni, Walid
    Carlson, Dawn
    Pradhan, Rajendra
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S669 - S669
12345